StockMacro
Menu

SELLAS Life Sciences

$13.66 +68% in 6 monthsMarket cap $2.8B

SLS on XNAS, Health Care, SELLAS Life Sciences Group, Inc., job postings

Measures activity, not value. Not investment advice.

Shares rose 836% in a year while short interest reached 28% of the shares.

  • GoodInstitutional holders rose to 214 from 189, up 13% from the prior quarter
  • BadNet loss $35.8M over 12 months, with $134.7M cash on hand

Written by AI from the data on this page, 22 Nov 2026. Not investment advice.

Profile and fundamentals

From its SEC filings, 12 months to 30 Sep 2026

SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.

Industry
Pharmaceutical preparations (Health Care)
Employees
13
Website
sellaslifesciences.com
Listed
Nasdaq, US
Last results
12 Nov 2026
Next results
expected around 7 Jan 2027 (an estimate: a year ago it reported on 8 Jan 2026)
Revenue and net income per quarter. Quarter to 30 Sep 2026: revenue $0, net loss $10.1M.
Quarter to 31 Dec 2021: revenue –, net income -$6.6MQuarter to 31 Mar 2022: revenue $1.0M, net income -$16.7MQuarter to 31 Mar 2022: revenue $1.0M, net income -$16.7MQuarter to 30 Jun 2022: revenue $0, net income -$8.4MQuarter to 30 Jun 2022: revenue $0, net income -$8.4MQuarter to 30 Sep 2022: revenue $0, net income -$7.0MQuarter to 30 Sep 2022: revenue $0, net income -$7.0MQuarter to 31 Dec 2022: revenue $0, net income -$9.1MQuarter to 31 Dec 2022: revenue $0, net income -$9.1MQuarter to 31 Mar 2023: revenue $0, net income -$11.1MQuarter to 31 Mar 2023: revenue $0, net income -$11.1MQuarter to 30 Jun 2023: revenue $0, net income -$8.8MQuarter to 30 Jun 2023: revenue $0, net income -$8.8MQuarter to 30 Sep 2023: revenue $0, net income -$9.3MQuarter to 30 Sep 2023: revenue $0, net income -$9.3MQuarter to 31 Dec 2023: revenue $0, net income -$8.1MQuarter to 31 Dec 2023: revenue $0, net income -$8.1MQuarter to 31 Mar 2024: revenue –, net income -$9.6MQuarter to 30 Jun 2024: revenue –, net income -$7.5MQuarter to 30 Sep 2024: revenue –, net income -$7.1MQuarter to 31 Dec 2024: revenue –, net income -$6.7MQuarter to 31 Mar 2025: revenue –, net income -$5.8MQuarter to 30 Jun 2025: revenue –, net income -$6.6MQuarter to 30 Sep 2025: revenue $0, net income -$6.8MQuarter to 30 Sep 2025: revenue $0, net income -$6.8MQuarter to 31 Dec 2025: revenue –, net income -$7.7MQuarter to 31 Mar 2026: revenue –, net income -$8.4MQuarter to 30 Jun 2026: revenue –, net income -$9.6MQuarter to 30 Sep 2026: revenue $0, net income -$10.1MQuarter to 30 Sep 2026: revenue $0, net income -$10.1M
31 Dec 2021RevenueNet incomeNet losstallest bar $16.7M30 Sep 2026
See the numbers
Quarter toRevenueNet income
30 Sep 2026$0-$10.1M
30 Jun 2026–-$9.6M
31 Mar 2026–-$8.4M
31 Dec 2025–-$7.7M
30 Sep 2025$0-$6.8M
30 Jun 2025–-$6.6M
31 Mar 2025–-$5.8M
31 Dec 2024–-$6.7M
30 Sep 2024–-$7.1M
30 Jun 2024–-$7.5M
31 Mar 2024–-$9.6M
31 Dec 2023$0-$8.1M
30 Sep 2023$0-$9.3M
30 Jun 2023$0-$8.8M
31 Mar 2023$0-$11.1M
31 Dec 2022$0-$9.1M
30 Sep 2022$0-$7.0M
30 Jun 2022$0-$8.4M
31 Mar 2022$1.0M-$16.7M
31 Dec 2021–-$6.6M
Fundamentals, 12 months to 30 Sep 2026
MeasureLatestYear beforePeer median
RevenueSales over the last 12 months reported. – –
Revenue growthRevenue of the last 12 months compared with the 12 months before. – +11%
Net incomeProfit after all costs and taxes over the last 12 months reported. Negative is a loss. -$35.8M -$25.9M
EPS (diluted)Earnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split). -$0.20 -$0.28
Gross marginWhat is left of each dollar of sales after the direct cost of making the product or service. – – 73.2%
Operating marginOperating income as a share of sales: profit from the business before interest and taxes. – – -25.0%
Net marginNet income as a share of sales: what the owners keep of each dollar sold. – – -18.2%
Return on equityNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money. -40.3% -58.8%
Free cash flowCash from operations minus capital spending over the last 12 months: cash the business produced. – –
CashCash, cash equivalents and short-term investments on the latest balance sheet. $134.7M $44.3M
DebtShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted. – –
Net debtDebt minus cash. Negative means the company holds more cash than it owes (net cash). – –
Debt to equityDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative. – 0.0
Book value per shareShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding. $0.65
P/EPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss. loss 19.3
P/SPrice to sales: market cap divided by revenue of the last 12 months. – 5.0
EV/SalesEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months. – 5.0
P/BPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative. 21.1 2.0

Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.

Peers nearest by market cap, its own industry first

CompanyMarket capP/EP/SRevenue growthNet margin
SELLAS Life SciencesSLS (this company) $2.8Bloss–––
Dyne TherapeuticsDYN $2.9Bloss–––
Acadia PharmaceuticalsACAD $3.0B8.22.5+15%30.1%
Bausch Health CompaniesBHC $3.1Bloss0.28+11%-7.6%
Xeris BiopharmaXERS $3.1Bloss8.4+38%-1.8%
XencorXNCR $2.5Bloss12.4+34%-58.8%

Insider Buy/Sell Shares the company's insiders (directors, officers and owners of 10% or more) bought minus what they sold on the open market in the last 90 days, from their Form 4 filings.

-$717K

bought $0, sold $717K

Institutional holders The number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.

+13%

214 13F filers vs 189

Institutional ownership Shares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.

35%

71.9M shares held by 13F filers (30 Sep 2026) of 203.9M outstanding (11 Nov 2026)

Short interest Shares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.

28%

57.1M shares sold short (30 Oct 2026) of 203.9M outstanding (11 Nov 2026)

Days to cover Short interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.

6.7

57.1M shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it

Short interest change How the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.

+6.3%

53.8M shares sold short in the report before, 57.1M on 30 Oct 2026

Short sale volume Share of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.

57%

57% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 57%

Open jobs Job postings open on the company's own careers site today, where we track it. Blank when we do not track this company's careers site yet.

–

We do not track this company's careers site yet.

Open jobs change How the number of open job postings changed over the last 30 days: total hiring demand, any job, any country. Shown only once we have tracked the company for 30 days.

–

We do not track this company's careers site yet.

Employees Total staff the company reported in its latest annual report (10-K), with the change from the year before when both years are reported.

–

No headcount in its annual reports in our data.

Visa hiring (foreign workers) Applications to hire foreign specialists on H-1B and E-3 visas certified by the Labor Department in the last 12 months, compared with the 12 months before. This is NOT total hiring: most hires need no visa. Open jobs shows total hiring where we track it.

–

No data for this company

Revenue growth Sales in the latest reported quarter compared with the same quarter a year earlier.

–

No data for this company

Capital spending Money spent on buildings, machines and equipment in the latest quarter, compared with the same quarter a year earlier.

–

No data for this company

Federal contracts Money the US government committed to the company in contracts and grants over the last 12 months.

–

No data for this company

Lobbying What the company reported spending on federal lobbying over the last four quarters.

–

No data for this company

Layoff notices Workers named in state WARN layoff notices over the last 12 months (employers must file them 60 days before a large layoff).

–

No data for this company

News (7d) Articles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.

129

129 articles in the last 7 days; its usual week has 6 (the median of the 26 weeks before).

News vs usual Articles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.

22×

129 articles in the last 7 days; its usual week has 6.

Price $13.66 on 20 Nov 2026, +836% over 12 months (12-month range $1.39 to $19.15)

  • Sharp change
  • 8-K and other filings
Insider net buying (open market). Insiders sold a net $717K in the last 12 months (the 12 months before: $185K).
H-1B/E-3 applications certified. H-1B/E-3 applications certified: 1 published in the last 12 months (none in the 12 months before).
Revenue per quarter. Revenue $0 in the latest quarter.
Institutional holders (13F filers). 214 13F filers reported holding it in the latest 13F quarter, +133% on a year earlier.

Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: capital spending per quarter, federal obligations, lobbying spend, workers in warn layoff notices.

See the numbers
Dated facts on the price chart (newest 100)
Became publicKindFact
25 Jun 20268-K and other filingsDirector or officer change
25 Jun 2026Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
19 May 2026Sharp changeMany funds opening a new position: many funds opening a new position, 59 vs usual 12.50 (2026-03-31); 3.5x the same period a year earlier
17 Feb 2026Sharp changeMany funds opening a new position: many funds opening a new position, 26 vs usual 8 (2025-12-31); 6.5x the same period a year earlier
16 Dec 2025Sharp changeShort interest spike: short interest spike, 33.3M vs usual 11.0M (2025-11-28); 3.7x the same period a year earlier
2 Dec 2025Sharp changeShort interest spike: short interest spike, 31.8M vs usual 9.4M (2025-11-14); 3.6x the same period a year earlier
18 Nov 2025Sharp changeShort interest spike: short interest spike, 29.0M vs usual 9.0M (2025-10-31); 3.4x the same period a year earlier
28 Oct 2025Sharp changeShort interest spike: short interest spike, 25.1M vs usual 8.9M (2025-10-15); 4.1x the same period a year earlier
14 Oct 2025Sharp changeShort interest spike: short interest spike, 23.1M vs usual 8.8M (2025-09-30); 2.8x the same period a year earlier
30 Sep 2025Sharp changeShort interest spike: short interest spike, 20.9M vs usual 8.7M (2025-09-15); 2.6x the same period a year earlier
16 Sep 2025Sharp changeShort interest spike: short interest spike, 29.3M vs usual 8.6M (2025-08-29); 3.6x the same period a year earlier
2 Sep 2025Sharp changeShort interest spike: short interest spike, 29.2M vs usual 8.4M (2025-08-15); 3.8x the same period a year earlier
14 Aug 2025Sharp changeMany funds opening a new position: many funds opening a new position, 38 vs usual 7.50 (2025-06-30); 4.8x the same period a year earlier
12 Aug 2025Sharp changeShort interest spike: short interest spike, 26.4M vs usual 8.4M (2025-07-31); 2.5x the same period a year earlier
29 Jul 2025Sharp changeShort interest spike: short interest spike, 27.7M vs usual 8.4M (2025-07-15); 2.9x the same period a year earlier
1 Jul 2025Sharp changeShort interest spike: short interest spike, 18.9M vs usual 8.2M (2025-06-13); 2.5x the same period a year earlier
17 Jun 2025Sharp changeShort interest spike: short interest spike, 12.2M vs usual 8.2M (2025-05-30); 1.6x the same period a year earlier
6 Jun 20258-K and other filingsChanged its auditor
16 Jan 20258-K and other filingsDirector or officer change
16 Jan 2025Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
30 Apr 2024Sharp changeShort interest spike: short interest spike, 5.7M vs usual 1.6M (2024-04-15); 4.8x the same period a year earlier
16 Apr 2024Sharp changeShort interest spike: short interest spike, 5.3M vs usual 1.2M (2024-03-28); 4.8x the same period a year earlier
2 Apr 2024Sharp changeShort interest spike: short interest spike, 5.2M vs usual 1.2M (2024-03-15); 4.3x the same period a year earlier
29 Mar 20248-K and other filingsPrivate placement of securities (Form D)
12 Mar 2024Sharp changeShort interest spike: short interest spike, 4.5M vs usual 1.2M (2024-02-29); 3.5x the same period a year earlier
8 Mar 20248-K and other filingsDirector or officer change
8 Mar 2024Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
5 Mar 2024Sharp changeShort interest spike: short interest spike, 3.9M vs usual 1.2M (2024-02-15); 3.2x the same period a year earlier
16 Feb 20248-K and other filingsDelisting notice or listing transfer
13 Feb 2024Sharp changeShort interest spike: short interest spike, 3.1M vs usual 1.2M (2024-01-31); 2.7x the same period a year earlier
30 Jan 2024Sharp changeShort interest spike: short interest spike, 3.9M vs usual 1.2M (2024-01-12); 3.2x the same period a year earlier
16 Jan 2024Sharp changeShort interest spike: short interest spike, 4.7M vs usual 1.2M (2023-12-29); 3.8x the same period a year earlier
3 Jan 20248-K and other filingsA major agreement ended
2 Jan 2024Sharp changeShort interest spike: short interest spike, 4.7M vs usual 1.2M (2023-12-15); 3.8x the same period a year earlier
12 Dec 2023Sharp changeShort interest spike: short interest spike, 4.6M vs usual 1.2M (2023-11-30); 3.8x the same period a year earlier
8 Dec 20238-K and other filingsDelisting notice or listing transfer
28 Nov 2023Sharp changeShort interest spike: short interest spike, 4.6M vs usual 1.2M (2023-11-15); 4.0x the same period a year earlier
14 Nov 2023Sharp changeShort interest spike: short interest spike, 3.0M vs usual 1.2M (2023-10-31); 3.1x the same period a year earlier
31 Oct 2023Sharp changeShort interest spike: short interest spike, 2.0M vs usual 1.2M (2023-10-13); 2.5x the same period a year earlier
6 Feb 20238-K and other filingsDirector or officer change
6 Feb 2023Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
17 Jan 2023Sharp changeShort interest spike: short interest spike, 1.2M vs usual 897K (2022-12-30); 1.6x the same period a year earlier
3 Jan 2023Sharp changeShort interest spike: short interest spike, 1.2M vs usual 892K (2022-12-15); 1.5x the same period a year earlier
13 Dec 2022Sharp changeShort interest spike: short interest spike, 1.2M vs usual 878K (2022-11-30); 1.7x the same period a year earlier
16 Aug 20228-K and other filingsDirector or officer change
16 Aug 2022Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
16 Dec 20218-K and other filingsDirector or officer change
16 Dec 2021Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
Insider net buying (open market)
Month from 1 Dec 2021: -$20K published
Month from 1 Dec 2022: -$26K published
Month from 1 May 2025: $36K published
Month from 1 Jun 2025: $49K published
Month from 1 Nov 2025: $101K published
Month from 1 Nov 2026: -$717K published
H-1B/E-3 applications certified
Quarter from 1 Jul 2026: 1 published
Revenue per quarter
Quarter ended 31 Mar 2022: $1.0M, -82% on a year earlier; public on 13 May 2022
Quarter ended 30 Jun 2022: $0, -100% on a year earlier; public on 12 Aug 2022
Quarter ended 30 Sep 2022: $0; public on 15 Nov 2022
Quarter ended 31 Dec 2022: $0; public on 17 Mar 2023
Quarter ended 31 Mar 2023: $0, -100% on a year earlier; public on 12 May 2023
Quarter ended 30 Jun 2023: $0; public on 11 Aug 2023
Quarter ended 30 Sep 2023: $0; public on 10 Nov 2023
Quarter ended 31 Dec 2023: $0; public on 29 Mar 2024
Quarter ended 30 Sep 2025: $0; public on 13 Nov 2026
Quarter ended 30 Sep 2026: $0; public on 13 Nov 2026
Institutional holders (13F filers)
31 Dec 2021 report: 25; public on 14 Feb 2022
31 Mar 2022 report: 25; public on 16 May 2022
30 Jun 2022 report: 26; public on 15 Aug 2022
30 Sep 2022 report: 27; public on 14 Nov 2022
31 Dec 2022 report: 28; public on 14 Feb 2023
31 Mar 2023 report: 23; public on 15 May 2023
30 Jun 2023 report: 20; public on 14 Aug 2023
30 Sep 2023 report: 24; public on 14 Nov 2023
31 Dec 2023 report: 29; public on 14 Feb 2024
31 Mar 2024 report: 28; public on 15 May 2024
30 Jun 2024 report: 27; public on 14 Aug 2024
30 Sep 2024 report: 31; public on 14 Nov 2024
31 Dec 2024 report: 31; public on 14 Feb 2025
31 Mar 2025 report: 43; public on 15 May 2025
30 Jun 2025 report: 75; public on 14 Aug 2025
30 Sep 2025 report: 92; public on 14 Nov 2025
31 Dec 2025 report: 108; public on 17 Feb 2026
31 Mar 2026 report: 157; public on 15 May 2026
30 Jun 2026 report: 189; public on 14 Aug 2026
30 Sep 2026 report: 214; public on 16 Nov 2026

What is unusual now

  • Nothing unusual in the last 90 days: no change appeared. Its most unusual measure now is insider open-market selling (USD, Form 4) at $717K (20 Nov 2026), 71× its normal reading; higher than 91% of its own history.
  • Insider net buying (open market): Insiders sold a net $717K in the last 12 months (the 12 months before: $185K).
  • H-1B/E-3 applications certified: H-1B/E-3 applications certified: 1 published in the last 12 months (none in the 12 months before).
  • Revenue per quarter: Revenue $0 in the latest quarter.

Latest records

The names and amounts behind the totals, newest first

Insider trades

All 17 insider trades

Last 90 days: 3 sales, $717K; no purchases. Open-market trades by officers, directors and 10% owners.

FiledInsiderTradeSharesPriceValueSource
20 Nov 2026John Thomas BurnsCFOSell3,831$19.18$73KForm 4
20 Nov 2026Dragan CicicSVP, Chief Development OfficerSell6,933$19.18$133KForm 4
20 Nov 2026Angelos M. StergiouPresident and CEOSell26,606$19.18$510KForm 4
21 Nov 2025Katherine Bach KalinDirectorBuy63,400$1.59$101KForm 4
13 Jun 2025Robert L Van NostrandDirectorBuy10,000$1.48$15KForm 4
2 Jun 2025Jane WasmanDirectorBuy20,000$1.69$34KForm 4
22 May 2025Katherine Bach KalinDirectorBuy20,000$1.80$36KForm 4
5 Dec 2022John Thomas BurnsSenior VP, Finance & CAOSell1,159$2.59$3KForm 4

214 institutions reported shares at the end of Q3 2026, 35% of the shares outstanding; 45 opened a position, 23 sold out. From 13F reports.

InstitutionShares% of companyValueChange vs Q2 2026
BlackRock, Inc.16.2M7.94%$199.2M+1.1M+7.4%
State Street Corp10.4M5.09%$127.7M-2.6M-20%
Vanguard Capital Management LLC8.9M4.39%$110.1M+717K+8.7%
Geode Capital Management, LLC5.2M2.54%$63.7M+288K+5.9%
Susquehanna International Group, LLP2.6M1.29%$32.5M+588K+29%
Vanguard Portfolio Management LLC2.3M1.13%$28.3M+136K+6.3%
Northern Trust Corp1.9M0.91%$22.8M+231K+14%
Charles Schwab Investment Management Inc1.8M0.88%$22.2M+1.2M+219%
Morgan Stanley1.5M0.74%$18.6M+275K+22%
UBS Group AG1.5M0.73%$18.3M+233K+19%

In 12 months: 1 director or officer change, 1 major agreement. Results releases and routine reports are left out.

FiledWhat happenedSource
20 Nov 2026Agreed to sell 11,538,462 common shares at $13.00 per share in an underwritten public offering; net proceeds about $161.8M8-K
25 Jun 2026Director or officer change8-K
27 Oct 2025Signed a major agreement8-K
3 Oct 2025Signed a major agreement8-K
11 Sep 2025Signed a major agreementSame filing: sold shares privately8-K
6 Jun 2025Changed its auditor8-K
29 Jan 2025Signed a major agreement8-K
16 Jan 2025Director or officer change8-K

The 5 newest of 476 articles that name the company.

Timeline

Several things at once

Two or more unrelated kinds of records unusual within 30 days

14 Aug 2025confirmed

Confirmed across sources Institutional holdings and Short interest and volume

SELLAS Life Sciences (SLS): saw 38 13F filers open a new position in the quarter ended 30 Jun 2025, 4.8× the same quarter last year, while it had 31.8M shares sold short in the 14 Nov 2025 report, 3.6× the same report last year. Two unrelated kinds of activity within 140 days.

  • Short interest and volume: Short interest spike, became public on 25 Jul 2025
  • Short interest and volume: Short interest spike, became public on 12 Aug 2025
  • Institutional holdings: Many funds opening a new position, became public on 14 Aug 2025
  • Short interest and volume: Short interest spike, became public on 27 Aug 2025
  • Short interest and volume: Short interest spike, became public on 11 Sep 2025
  • Short interest and volume: Short interest spike, became public on 25 Sep 2025
  • Short interest and volume: Short interest spike, became public on 10 Oct 2025
  • Short interest and volume: Short interest spike, became public on 25 Oct 2025
  • Short interest and volume: Short interest spike, became public on 13 Nov 2025
  • Short interest and volume: Short interest spike, became public on 26 Nov 2025
  • Short interest and volume: Short interest spike, became public on 10 Dec 2025
2023-06-30: 32023-09-30: 32023-12-31: 82024-03-31: 72024-06-30: 82024-09-30: 82024-12-31: 42025-03-31: 172025-06-30: 38
The quarter ended 30 Jun 2025 against the 8 quarters before it. this quarterearliernormal: 7.5
See the evidence (11 changes)

Short interest and volume: Short interest spike became public on 25 Jul 2025

SELLAS Life Sciences had 27.7M shares sold short in the 15 Jul 2025 report, 2.9× the same report last year.

This period
27.7M (the 15 Jul 2025 report)
Normal report (median of 24 earlier)
8.4M
Typical spread (median absolute deviation)
621K
How far from its usual level
+21.0
Same report last year
9.7M
History used
2,741 days
2024-07-15: 9.7M2024-07-31: 10.7M2024-08-15: 7.7M2024-08-30: 8.2M2024-09-13: 8.2M2024-09-30: 8.2M2024-10-15: 6.1M2024-10-31: 8.6M2024-11-15: 8.8M2024-11-29: 9.0M2024-12-13: 7.5M2024-12-31: 8.0M2025-01-15: 9.0M2025-01-31: 9.8M2025-02-14: 8.7M2025-02-28: 7.8M2025-03-14: 7.8M2025-03-31: 8.2M2025-04-15: 7.8M2025-04-30: 7.7M2025-05-15: 8.8M2025-05-30: 12.2M2025-06-13: 18.9M2025-06-30: 24.4M2025-07-15: 27.7M
the 15 Jul 2025 report24 earlier reportsnormal: 8.4M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 12 Aug 2025

SELLAS Life Sciences had 26.4M shares sold short in the 31 Jul 2025 report, 2.5× the same report last year.

This period
26.4M (the 31 Jul 2025 report)
Normal report (median of 24 earlier)
8.4M
Typical spread (median absolute deviation)
621K
How far from its usual level
+19.6
Same report last year
10.7M
History used
2,757 days
2024-07-31: 10.7M2024-08-15: 7.7M2024-08-30: 8.2M2024-09-13: 8.2M2024-09-30: 8.2M2024-10-15: 6.1M2024-10-31: 8.6M2024-11-15: 8.8M2024-11-29: 9.0M2024-12-13: 7.5M2024-12-31: 8.0M2025-01-15: 9.0M2025-01-31: 9.8M2025-02-14: 8.7M2025-02-28: 7.8M2025-03-14: 7.8M2025-03-31: 8.2M2025-04-15: 7.8M2025-04-30: 7.7M2025-05-15: 8.8M2025-05-30: 12.2M2025-06-13: 18.9M2025-06-30: 24.4M2025-07-15: 27.7M2025-07-31: 26.4M
the 31 Jul 2025 report24 earlier reportsnormal: 8.4M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Institutional holdings: Many funds opening a new position became public on 14 Aug 2025

SELLAS Life Sciences saw 38 13F filers open a new position in the quarter ended 30 Jun 2025, 4.8× the same quarter last year.

This period
38 (the quarter ended 30 Jun 2025)
Normal quarter (median of 8 earlier)
7.5
Typical spread (median absolute deviation)
2
How far from its usual level
+10.2
Same quarter last year
8
History used
2,648 days
2023-06-30: 32023-09-30: 32023-12-31: 82024-03-31: 72024-06-30: 82024-09-30: 82024-12-31: 42025-03-31: 172025-06-30: 38
the quarter ended 30 Jun 20258 earlier quartersnormal: 7.5

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

Check it at the source: SEC Form 13F data sets.

Short interest and volume: Short interest spike became public on 27 Aug 2025

SELLAS Life Sciences had 29.2M shares sold short in the 15 Aug 2025 report, 3.8× the same report last year.

This period
29.2M (the 15 Aug 2025 report)
Normal report (median of 24 earlier)
8.4M
Typical spread (median absolute deviation)
621K
How far from its usual level
+22.5
Same report last year
7.7M
History used
2,772 days
2024-08-15: 7.7M2024-08-30: 8.2M2024-09-13: 8.2M2024-09-30: 8.2M2024-10-15: 6.1M2024-10-31: 8.6M2024-11-15: 8.8M2024-11-29: 9.0M2024-12-13: 7.5M2024-12-31: 8.0M2025-01-15: 9.0M2025-01-31: 9.8M2025-02-14: 8.7M2025-02-28: 7.8M2025-03-14: 7.8M2025-03-31: 8.2M2025-04-15: 7.8M2025-04-30: 7.7M2025-05-15: 8.8M2025-05-30: 12.2M2025-06-13: 18.9M2025-06-30: 24.4M2025-07-15: 27.7M2025-07-31: 26.4M2025-08-15: 29.2M
the 15 Aug 2025 report24 earlier reportsnormal: 8.4M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 11 Sep 2025

SELLAS Life Sciences had 29.3M shares sold short in the 29 Aug 2025 report, 3.6× the same report last year.

This period
29.3M (the 29 Aug 2025 report)
Normal report (median of 24 earlier)
8.6M
Typical spread (median absolute deviation)
806K
How far from its usual level
+17.3
Same report last year
8.2M
History used
2,786 days
2024-08-30: 8.2M2024-09-13: 8.2M2024-09-30: 8.2M2024-10-15: 6.1M2024-10-31: 8.6M2024-11-15: 8.8M2024-11-29: 9.0M2024-12-13: 7.5M2024-12-31: 8.0M2025-01-15: 9.0M2025-01-31: 9.8M2025-02-14: 8.7M2025-02-28: 7.8M2025-03-14: 7.8M2025-03-31: 8.2M2025-04-15: 7.8M2025-04-30: 7.7M2025-05-15: 8.8M2025-05-30: 12.2M2025-06-13: 18.9M2025-06-30: 24.4M2025-07-15: 27.7M2025-07-31: 26.4M2025-08-15: 29.2M2025-08-29: 29.3M
the 29 Aug 2025 report24 earlier reportsnormal: 8.6M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 25 Sep 2025

SELLAS Life Sciences had 20.9M shares sold short in the 15 Sep 2025 report, 2.6× the same report last year.

This period
20.9M (the 15 Sep 2025 report)
Normal report (median of 24 earlier)
8.7M
Typical spread (median absolute deviation)
914K
How far from its usual level
+9.0
Same report last year
8.2M
History used
2,803 days
2024-09-13: 8.2M2024-09-30: 8.2M2024-10-15: 6.1M2024-10-31: 8.6M2024-11-15: 8.8M2024-11-29: 9.0M2024-12-13: 7.5M2024-12-31: 8.0M2025-01-15: 9.0M2025-01-31: 9.8M2025-02-14: 8.7M2025-02-28: 7.8M2025-03-14: 7.8M2025-03-31: 8.2M2025-04-15: 7.8M2025-04-30: 7.7M2025-05-15: 8.8M2025-05-30: 12.2M2025-06-13: 18.9M2025-06-30: 24.4M2025-07-15: 27.7M2025-07-31: 26.4M2025-08-15: 29.2M2025-08-29: 29.3M2025-09-15: 20.9M
the 15 Sep 2025 report24 earlier reportsnormal: 8.7M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 10 Oct 2025

SELLAS Life Sciences had 23.1M shares sold short in the 30 Sep 2025 report, 2.8× the same report last year.

This period
23.1M (the 30 Sep 2025 report)
Normal report (median of 24 earlier)
8.8M
Typical spread (median absolute deviation)
1.0M
How far from its usual level
+9.5
Same report last year
8.2M
History used
2,818 days
2024-09-30: 8.2M2024-10-15: 6.1M2024-10-31: 8.6M2024-11-15: 8.8M2024-11-29: 9.0M2024-12-13: 7.5M2024-12-31: 8.0M2025-01-15: 9.0M2025-01-31: 9.8M2025-02-14: 8.7M2025-02-28: 7.8M2025-03-14: 7.8M2025-03-31: 8.2M2025-04-15: 7.8M2025-04-30: 7.7M2025-05-15: 8.8M2025-05-30: 12.2M2025-06-13: 18.9M2025-06-30: 24.4M2025-07-15: 27.7M2025-07-31: 26.4M2025-08-15: 29.2M2025-08-29: 29.3M2025-09-15: 20.9M2025-09-30: 23.1M
the 30 Sep 2025 report24 earlier reportsnormal: 8.8M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 25 Oct 2025

SELLAS Life Sciences had 25.1M shares sold short in the 15 Oct 2025 report, 4.1× the same report last year.

This period
25.1M (the 15 Oct 2025 report)
Normal report (median of 24 earlier)
8.9M
Typical spread (median absolute deviation)
1.1M
How far from its usual level
+9.6
Same report last year
6.1M
History used
2,833 days
2024-10-15: 6.1M2024-10-31: 8.6M2024-11-15: 8.8M2024-11-29: 9.0M2024-12-13: 7.5M2024-12-31: 8.0M2025-01-15: 9.0M2025-01-31: 9.8M2025-02-14: 8.7M2025-02-28: 7.8M2025-03-14: 7.8M2025-03-31: 8.2M2025-04-15: 7.8M2025-04-30: 7.7M2025-05-15: 8.8M2025-05-30: 12.2M2025-06-13: 18.9M2025-06-30: 24.4M2025-07-15: 27.7M2025-07-31: 26.4M2025-08-15: 29.2M2025-08-29: 29.3M2025-09-15: 20.9M2025-09-30: 23.1M2025-10-15: 25.1M
the 15 Oct 2025 report24 earlier reportsnormal: 8.9M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 13 Nov 2025

SELLAS Life Sciences had 29.0M shares sold short in the 31 Oct 2025 report, 3.4× the same report last year.

This period
29.0M (the 31 Oct 2025 report)
Normal report (median of 24 earlier)
9.0M
Typical spread (median absolute deviation)
1.3M
How far from its usual level
+10.5
Same report last year
8.6M
History used
2,849 days
2024-10-31: 8.6M2024-11-15: 8.8M2024-11-29: 9.0M2024-12-13: 7.5M2024-12-31: 8.0M2025-01-15: 9.0M2025-01-31: 9.8M2025-02-14: 8.7M2025-02-28: 7.8M2025-03-14: 7.8M2025-03-31: 8.2M2025-04-15: 7.8M2025-04-30: 7.7M2025-05-15: 8.8M2025-05-30: 12.2M2025-06-13: 18.9M2025-06-30: 24.4M2025-07-15: 27.7M2025-07-31: 26.4M2025-08-15: 29.2M2025-08-29: 29.3M2025-09-15: 20.9M2025-09-30: 23.1M2025-10-15: 25.1M2025-10-31: 29.0M
the 31 Oct 2025 report24 earlier reportsnormal: 9.0M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 26 Nov 2025

SELLAS Life Sciences had 31.8M shares sold short in the 14 Nov 2025 report, 3.6× the same report last year.

This period
31.8M (the 14 Nov 2025 report)
Normal report (median of 24 earlier)
9.4M
Typical spread (median absolute deviation)
1.8M
How far from its usual level
+8.2
Same report last year
8.8M
History used
2,863 days
2024-11-15: 8.8M2024-11-29: 9.0M2024-12-13: 7.5M2024-12-31: 8.0M2025-01-15: 9.0M2025-01-31: 9.8M2025-02-14: 8.7M2025-02-28: 7.8M2025-03-14: 7.8M2025-03-31: 8.2M2025-04-15: 7.8M2025-04-30: 7.7M2025-05-15: 8.8M2025-05-30: 12.2M2025-06-13: 18.9M2025-06-30: 24.4M2025-07-15: 27.7M2025-07-31: 26.4M2025-08-15: 29.2M2025-08-29: 29.3M2025-09-15: 20.9M2025-09-30: 23.1M2025-10-15: 25.1M2025-10-31: 29.0M2025-11-14: 31.8M
the 14 Nov 2025 report24 earlier reportsnormal: 9.4M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 10 Dec 2025

SELLAS Life Sciences had 33.3M shares sold short in the 28 Nov 2025 report, 3.7× the same report last year.

This period
33.3M (the 28 Nov 2025 report)
Normal report (median of 24 earlier)
11.0M
Typical spread (median absolute deviation)
3.4M
How far from its usual level
+4.4
Same report last year
9.0M
History used
2,877 days
2024-11-29: 9.0M2024-12-13: 7.5M2024-12-31: 8.0M2025-01-15: 9.0M2025-01-31: 9.8M2025-02-14: 8.7M2025-02-28: 7.8M2025-03-14: 7.8M2025-03-31: 8.2M2025-04-15: 7.8M2025-04-30: 7.7M2025-05-15: 8.8M2025-05-30: 12.2M2025-06-13: 18.9M2025-06-30: 24.4M2025-07-15: 27.7M2025-07-31: 26.4M2025-08-15: 29.2M2025-08-29: 29.3M2025-09-15: 20.9M2025-09-30: 23.1M2025-10-15: 25.1M2025-10-31: 29.0M2025-11-14: 31.8M2025-11-28: 33.3M
the 28 Nov 2025 report24 earlier reportsnormal: 11.0M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

Timeline

Changes and notable records, by the date each became public

  1. 25 Jun 2026Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  2. 25 Jun 2026Filings record

    Director or officer change

  3. 15 May 2026Institutional holdings change

    saw 59 13F filers open a new position in the quarter ended 31 Mar 2026, 3.5× the same quarter last year.

    Same quarter last year: 17; its normal quarter is 12.5.

    See the evidence
    This period
    59 (the quarter ended 31 Mar 2026)
    Normal quarter (median of 8 earlier)
    12.5
    Typical spread (median absolute deviation)
    5.5
    How far from its usual level
    +5.7
    Same quarter last year
    17
    History used
    2,922 days
    2024-03-31: 72024-06-30: 82024-09-30: 82024-12-31: 42025-03-31: 172025-06-30: 382025-09-30: 182025-12-31: 262026-03-31: 59
    the quarter ended 31 Mar 20268 earlier quartersnormal: 12.5

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

    Check it at the source: SEC Form 13F data sets.

  4. 17 Feb 2026Institutional holdings change

    saw 26 13F filers open a new position in the quarter ended 31 Dec 2025, 6.5× the same quarter last year.

    Same quarter last year: 4; its normal quarter is 8.

    See the evidence
    This period
    26 (the quarter ended 31 Dec 2025)
    Normal quarter (median of 8 earlier)
    8
    Typical spread (median absolute deviation)
    2.5
    How far from its usual level
    +4.9
    Same quarter last year
    4
    History used
    2,832 days
    2023-12-31: 82024-03-31: 72024-06-30: 82024-09-30: 82024-12-31: 42025-03-31: 172025-06-30: 382025-09-30: 182025-12-31: 26
    the quarter ended 31 Dec 20258 earlier quartersnormal: 8

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

    Check it at the source: SEC Form 13F data sets.

  5. 10 Dec 2025Short interest and volume change

    had 33.3M shares sold short in the 28 Nov 2025 report, 3.7× the same report last year.

    Same report last year: 9.0M; its normal report is 11.0M.

    See the evidence
    This period
    33.3M (the 28 Nov 2025 report)
    Normal report (median of 24 earlier)
    11.0M
    Typical spread (median absolute deviation)
    3.4M
    How far from its usual level
    +4.4
    Same report last year
    9.0M
    History used
    2,877 days
    2024-11-29: 9.0M2024-12-13: 7.5M2024-12-31: 8.0M2025-01-15: 9.0M2025-01-31: 9.8M2025-02-14: 8.7M2025-02-28: 7.8M2025-03-14: 7.8M2025-03-31: 8.2M2025-04-15: 7.8M2025-04-30: 7.7M2025-05-15: 8.8M2025-05-30: 12.2M2025-06-13: 18.9M2025-06-30: 24.4M2025-07-15: 27.7M2025-07-31: 26.4M2025-08-15: 29.2M2025-08-29: 29.3M2025-09-15: 20.9M2025-09-30: 23.1M2025-10-15: 25.1M2025-10-31: 29.0M2025-11-14: 31.8M2025-11-28: 33.3M
    the 28 Nov 2025 report24 earlier reportsnormal: 11.0M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  6. 26 Nov 2025Short interest and volume change

    had 31.8M shares sold short in the 14 Nov 2025 report, 3.6× the same report last year.

    Same report last year: 8.8M; its normal report is 9.4M.

    See the evidence
    This period
    31.8M (the 14 Nov 2025 report)
    Normal report (median of 24 earlier)
    9.4M
    Typical spread (median absolute deviation)
    1.8M
    How far from its usual level
    +8.2
    Same report last year
    8.8M
    History used
    2,863 days
    2024-11-15: 8.8M2024-11-29: 9.0M2024-12-13: 7.5M2024-12-31: 8.0M2025-01-15: 9.0M2025-01-31: 9.8M2025-02-14: 8.7M2025-02-28: 7.8M2025-03-14: 7.8M2025-03-31: 8.2M2025-04-15: 7.8M2025-04-30: 7.7M2025-05-15: 8.8M2025-05-30: 12.2M2025-06-13: 18.9M2025-06-30: 24.4M2025-07-15: 27.7M2025-07-31: 26.4M2025-08-15: 29.2M2025-08-29: 29.3M2025-09-15: 20.9M2025-09-30: 23.1M2025-10-15: 25.1M2025-10-31: 29.0M2025-11-14: 31.8M
    the 14 Nov 2025 report24 earlier reportsnormal: 9.4M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  7. 22 Nov 2025Insiders record

    Kalin Katherine Bach (director) bought 63,400 shares of SLS ($100,806) (dated 21 Nov 2025)

  8. 13 Nov 2025Short interest and volume change

    had 29.0M shares sold short in the 31 Oct 2025 report, 3.4× the same report last year.

    Same report last year: 8.6M; its normal report is 9.0M.

    See the evidence
    This period
    29.0M (the 31 Oct 2025 report)
    Normal report (median of 24 earlier)
    9.0M
    Typical spread (median absolute deviation)
    1.3M
    How far from its usual level
    +10.5
    Same report last year
    8.6M
    History used
    2,849 days
    2024-10-31: 8.6M2024-11-15: 8.8M2024-11-29: 9.0M2024-12-13: 7.5M2024-12-31: 8.0M2025-01-15: 9.0M2025-01-31: 9.8M2025-02-14: 8.7M2025-02-28: 7.8M2025-03-14: 7.8M2025-03-31: 8.2M2025-04-15: 7.8M2025-04-30: 7.7M2025-05-15: 8.8M2025-05-30: 12.2M2025-06-13: 18.9M2025-06-30: 24.4M2025-07-15: 27.7M2025-07-31: 26.4M2025-08-15: 29.2M2025-08-29: 29.3M2025-09-15: 20.9M2025-09-30: 23.1M2025-10-15: 25.1M2025-10-31: 29.0M
    the 31 Oct 2025 report24 earlier reportsnormal: 9.0M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  9. 25 Oct 2025Short interest and volume change

    had 25.1M shares sold short in the 15 Oct 2025 report, 4.1× the same report last year.

    Same report last year: 6.1M; its normal report is 8.9M.

    See the evidence
    This period
    25.1M (the 15 Oct 2025 report)
    Normal report (median of 24 earlier)
    8.9M
    Typical spread (median absolute deviation)
    1.1M
    How far from its usual level
    +9.6
    Same report last year
    6.1M
    History used
    2,833 days
    2024-10-15: 6.1M2024-10-31: 8.6M2024-11-15: 8.8M2024-11-29: 9.0M2024-12-13: 7.5M2024-12-31: 8.0M2025-01-15: 9.0M2025-01-31: 9.8M2025-02-14: 8.7M2025-02-28: 7.8M2025-03-14: 7.8M2025-03-31: 8.2M2025-04-15: 7.8M2025-04-30: 7.7M2025-05-15: 8.8M2025-05-30: 12.2M2025-06-13: 18.9M2025-06-30: 24.4M2025-07-15: 27.7M2025-07-31: 26.4M2025-08-15: 29.2M2025-08-29: 29.3M2025-09-15: 20.9M2025-09-30: 23.1M2025-10-15: 25.1M
    the 15 Oct 2025 report24 earlier reportsnormal: 8.9M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  10. 10 Oct 2025Short interest and volume change

    had 23.1M shares sold short in the 30 Sep 2025 report, 2.8× the same report last year.

    Same report last year: 8.2M; its normal report is 8.8M.

    See the evidence
    This period
    23.1M (the 30 Sep 2025 report)
    Normal report (median of 24 earlier)
    8.8M
    Typical spread (median absolute deviation)
    1.0M
    How far from its usual level
    +9.5
    Same report last year
    8.2M
    History used
    2,818 days
    2024-09-30: 8.2M2024-10-15: 6.1M2024-10-31: 8.6M2024-11-15: 8.8M2024-11-29: 9.0M2024-12-13: 7.5M2024-12-31: 8.0M2025-01-15: 9.0M2025-01-31: 9.8M2025-02-14: 8.7M2025-02-28: 7.8M2025-03-14: 7.8M2025-03-31: 8.2M2025-04-15: 7.8M2025-04-30: 7.7M2025-05-15: 8.8M2025-05-30: 12.2M2025-06-13: 18.9M2025-06-30: 24.4M2025-07-15: 27.7M2025-07-31: 26.4M2025-08-15: 29.2M2025-08-29: 29.3M2025-09-15: 20.9M2025-09-30: 23.1M
    the 30 Sep 2025 report24 earlier reportsnormal: 8.8M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  11. 25 Sep 2025Short interest and volume change

    had 20.9M shares sold short in the 15 Sep 2025 report, 2.6× the same report last year.

    Same report last year: 8.2M; its normal report is 8.7M.

    See the evidence
    This period
    20.9M (the 15 Sep 2025 report)
    Normal report (median of 24 earlier)
    8.7M
    Typical spread (median absolute deviation)
    914K
    How far from its usual level
    +9.0
    Same report last year
    8.2M
    History used
    2,803 days
    2024-09-13: 8.2M2024-09-30: 8.2M2024-10-15: 6.1M2024-10-31: 8.6M2024-11-15: 8.8M2024-11-29: 9.0M2024-12-13: 7.5M2024-12-31: 8.0M2025-01-15: 9.0M2025-01-31: 9.8M2025-02-14: 8.7M2025-02-28: 7.8M2025-03-14: 7.8M2025-03-31: 8.2M2025-04-15: 7.8M2025-04-30: 7.7M2025-05-15: 8.8M2025-05-30: 12.2M2025-06-13: 18.9M2025-06-30: 24.4M2025-07-15: 27.7M2025-07-31: 26.4M2025-08-15: 29.2M2025-08-29: 29.3M2025-09-15: 20.9M
    the 15 Sep 2025 report24 earlier reportsnormal: 8.7M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  12. 11 Sep 2025Short interest and volume change

    had 29.3M shares sold short in the 29 Aug 2025 report, 3.6× the same report last year.

    Same report last year: 8.2M; its normal report is 8.6M.

    See the evidence
    This period
    29.3M (the 29 Aug 2025 report)
    Normal report (median of 24 earlier)
    8.6M
    Typical spread (median absolute deviation)
    806K
    How far from its usual level
    +17.3
    Same report last year
    8.2M
    History used
    2,786 days
    2024-08-30: 8.2M2024-09-13: 8.2M2024-09-30: 8.2M2024-10-15: 6.1M2024-10-31: 8.6M2024-11-15: 8.8M2024-11-29: 9.0M2024-12-13: 7.5M2024-12-31: 8.0M2025-01-15: 9.0M2025-01-31: 9.8M2025-02-14: 8.7M2025-02-28: 7.8M2025-03-14: 7.8M2025-03-31: 8.2M2025-04-15: 7.8M2025-04-30: 7.7M2025-05-15: 8.8M2025-05-30: 12.2M2025-06-13: 18.9M2025-06-30: 24.4M2025-07-15: 27.7M2025-07-31: 26.4M2025-08-15: 29.2M2025-08-29: 29.3M
    the 29 Aug 2025 report24 earlier reportsnormal: 8.6M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  13. 27 Aug 2025Short interest and volume change

    had 29.2M shares sold short in the 15 Aug 2025 report, 3.8× the same report last year.

    Same report last year: 7.7M; its normal report is 8.4M.

    See the evidence
    This period
    29.2M (the 15 Aug 2025 report)
    Normal report (median of 24 earlier)
    8.4M
    Typical spread (median absolute deviation)
    621K
    How far from its usual level
    +22.5
    Same report last year
    7.7M
    History used
    2,772 days
    2024-08-15: 7.7M2024-08-30: 8.2M2024-09-13: 8.2M2024-09-30: 8.2M2024-10-15: 6.1M2024-10-31: 8.6M2024-11-15: 8.8M2024-11-29: 9.0M2024-12-13: 7.5M2024-12-31: 8.0M2025-01-15: 9.0M2025-01-31: 9.8M2025-02-14: 8.7M2025-02-28: 7.8M2025-03-14: 7.8M2025-03-31: 8.2M2025-04-15: 7.8M2025-04-30: 7.7M2025-05-15: 8.8M2025-05-30: 12.2M2025-06-13: 18.9M2025-06-30: 24.4M2025-07-15: 27.7M2025-07-31: 26.4M2025-08-15: 29.2M
    the 15 Aug 2025 report24 earlier reportsnormal: 8.4M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  14. 14 Aug 2025several at once

    saw 38 13F filers open a new position in the quarter ended 30 Jun 2025, 4.8× the same quarter last year, while it had 31.8M shares sold short in the 14 Nov 2025 report, 3.6× the same report last year. Two unrelated kinds of activity within 140 days.

    See the evidence (11 changes)

    Short interest and volume: Short interest spike became public on 25 Jul 2025

    SELLAS Life Sciences had 27.7M shares sold short in the 15 Jul 2025 report, 2.9× the same report last year.

    This period
    27.7M (the 15 Jul 2025 report)
    Normal report (median of 24 earlier)
    8.4M
    Typical spread (median absolute deviation)
    621K
    How far from its usual level
    +21.0
    Same report last year
    9.7M
    History used
    2,741 days
    2024-07-15: 9.7M2024-07-31: 10.7M2024-08-15: 7.7M2024-08-30: 8.2M2024-09-13: 8.2M2024-09-30: 8.2M2024-10-15: 6.1M2024-10-31: 8.6M2024-11-15: 8.8M2024-11-29: 9.0M2024-12-13: 7.5M2024-12-31: 8.0M2025-01-15: 9.0M2025-01-31: 9.8M2025-02-14: 8.7M2025-02-28: 7.8M2025-03-14: 7.8M2025-03-31: 8.2M2025-04-15: 7.8M2025-04-30: 7.7M2025-05-15: 8.8M2025-05-30: 12.2M2025-06-13: 18.9M2025-06-30: 24.4M2025-07-15: 27.7M
    the 15 Jul 2025 report24 earlier reportsnormal: 8.4M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Short interest and volume: Short interest spike became public on 12 Aug 2025

    SELLAS Life Sciences had 26.4M shares sold short in the 31 Jul 2025 report, 2.5× the same report last year.

    This period
    26.4M (the 31 Jul 2025 report)
    Normal report (median of 24 earlier)
    8.4M
    Typical spread (median absolute deviation)
    621K
    How far from its usual level
    +19.6
    Same report last year
    10.7M
    History used
    2,757 days
    2024-07-31: 10.7M2024-08-15: 7.7M2024-08-30: 8.2M2024-09-13: 8.2M2024-09-30: 8.2M2024-10-15: 6.1M2024-10-31: 8.6M2024-11-15: 8.8M2024-11-29: 9.0M2024-12-13: 7.5M2024-12-31: 8.0M2025-01-15: 9.0M2025-01-31: 9.8M2025-02-14: 8.7M2025-02-28: 7.8M2025-03-14: 7.8M2025-03-31: 8.2M2025-04-15: 7.8M2025-04-30: 7.7M2025-05-15: 8.8M2025-05-30: 12.2M2025-06-13: 18.9M2025-06-30: 24.4M2025-07-15: 27.7M2025-07-31: 26.4M
    the 31 Jul 2025 report24 earlier reportsnormal: 8.4M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Institutional holdings: Many funds opening a new position became public on 14 Aug 2025

    SELLAS Life Sciences saw 38 13F filers open a new position in the quarter ended 30 Jun 2025, 4.8× the same quarter last year.

    This period
    38 (the quarter ended 30 Jun 2025)
    Normal quarter (median of 8 earlier)
    7.5
    Typical spread (median absolute deviation)
    2
    How far from its usual level
    +10.2
    Same quarter last year
    8
    History used
    2,648 days
    2023-06-30: 32023-09-30: 32023-12-31: 82024-03-31: 72024-06-30: 82024-09-30: 82024-12-31: 42025-03-31: 172025-06-30: 38
    the quarter ended 30 Jun 20258 earlier quartersnormal: 7.5

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

    Check it at the source: SEC Form 13F data sets.

    Short interest and volume: Short interest spike became public on 27 Aug 2025

    SELLAS Life Sciences had 29.2M shares sold short in the 15 Aug 2025 report, 3.8× the same report last year.

    This period
    29.2M (the 15 Aug 2025 report)
    Normal report (median of 24 earlier)
    8.4M
    Typical spread (median absolute deviation)
    621K
    How far from its usual level
    +22.5
    Same report last year
    7.7M
    History used
    2,772 days
    2024-08-15: 7.7M2024-08-30: 8.2M2024-09-13: 8.2M2024-09-30: 8.2M2024-10-15: 6.1M2024-10-31: 8.6M2024-11-15: 8.8M2024-11-29: 9.0M2024-12-13: 7.5M2024-12-31: 8.0M2025-01-15: 9.0M2025-01-31: 9.8M2025-02-14: 8.7M2025-02-28: 7.8M2025-03-14: 7.8M2025-03-31: 8.2M2025-04-15: 7.8M2025-04-30: 7.7M2025-05-15: 8.8M2025-05-30: 12.2M2025-06-13: 18.9M2025-06-30: 24.4M2025-07-15: 27.7M2025-07-31: 26.4M2025-08-15: 29.2M
    the 15 Aug 2025 report24 earlier reportsnormal: 8.4M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Short interest and volume: Short interest spike became public on 11 Sep 2025

    SELLAS Life Sciences had 29.3M shares sold short in the 29 Aug 2025 report, 3.6× the same report last year.

    This period
    29.3M (the 29 Aug 2025 report)
    Normal report (median of 24 earlier)
    8.6M
    Typical spread (median absolute deviation)
    806K
    How far from its usual level
    +17.3
    Same report last year
    8.2M
    History used
    2,786 days
    2024-08-30: 8.2M2024-09-13: 8.2M2024-09-30: 8.2M2024-10-15: 6.1M2024-10-31: 8.6M2024-11-15: 8.8M2024-11-29: 9.0M2024-12-13: 7.5M2024-12-31: 8.0M2025-01-15: 9.0M2025-01-31: 9.8M2025-02-14: 8.7M2025-02-28: 7.8M2025-03-14: 7.8M2025-03-31: 8.2M2025-04-15: 7.8M2025-04-30: 7.7M2025-05-15: 8.8M2025-05-30: 12.2M2025-06-13: 18.9M2025-06-30: 24.4M2025-07-15: 27.7M2025-07-31: 26.4M2025-08-15: 29.2M2025-08-29: 29.3M
    the 29 Aug 2025 report24 earlier reportsnormal: 8.6M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Short interest and volume: Short interest spike became public on 25 Sep 2025

    SELLAS Life Sciences had 20.9M shares sold short in the 15 Sep 2025 report, 2.6× the same report last year.

    This period
    20.9M (the 15 Sep 2025 report)
    Normal report (median of 24 earlier)
    8.7M
    Typical spread (median absolute deviation)
    914K
    How far from its usual level
    +9.0
    Same report last year
    8.2M
    History used
    2,803 days
    2024-09-13: 8.2M2024-09-30: 8.2M2024-10-15: 6.1M2024-10-31: 8.6M2024-11-15: 8.8M2024-11-29: 9.0M2024-12-13: 7.5M2024-12-31: 8.0M2025-01-15: 9.0M2025-01-31: 9.8M2025-02-14: 8.7M2025-02-28: 7.8M2025-03-14: 7.8M2025-03-31: 8.2M2025-04-15: 7.8M2025-04-30: 7.7M2025-05-15: 8.8M2025-05-30: 12.2M2025-06-13: 18.9M2025-06-30: 24.4M2025-07-15: 27.7M2025-07-31: 26.4M2025-08-15: 29.2M2025-08-29: 29.3M2025-09-15: 20.9M
    the 15 Sep 2025 report24 earlier reportsnormal: 8.7M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Short interest and volume: Short interest spike became public on 10 Oct 2025

    SELLAS Life Sciences had 23.1M shares sold short in the 30 Sep 2025 report, 2.8× the same report last year.

    This period
    23.1M (the 30 Sep 2025 report)
    Normal report (median of 24 earlier)
    8.8M
    Typical spread (median absolute deviation)
    1.0M
    How far from its usual level
    +9.5
    Same report last year
    8.2M
    History used
    2,818 days
    2024-09-30: 8.2M2024-10-15: 6.1M2024-10-31: 8.6M2024-11-15: 8.8M2024-11-29: 9.0M2024-12-13: 7.5M2024-12-31: 8.0M2025-01-15: 9.0M2025-01-31: 9.8M2025-02-14: 8.7M2025-02-28: 7.8M2025-03-14: 7.8M2025-03-31: 8.2M2025-04-15: 7.8M2025-04-30: 7.7M2025-05-15: 8.8M2025-05-30: 12.2M2025-06-13: 18.9M2025-06-30: 24.4M2025-07-15: 27.7M2025-07-31: 26.4M2025-08-15: 29.2M2025-08-29: 29.3M2025-09-15: 20.9M2025-09-30: 23.1M
    the 30 Sep 2025 report24 earlier reportsnormal: 8.8M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Short interest and volume: Short interest spike became public on 25 Oct 2025

    SELLAS Life Sciences had 25.1M shares sold short in the 15 Oct 2025 report, 4.1× the same report last year.

    This period
    25.1M (the 15 Oct 2025 report)
    Normal report (median of 24 earlier)
    8.9M
    Typical spread (median absolute deviation)
    1.1M
    How far from its usual level
    +9.6
    Same report last year
    6.1M
    History used
    2,833 days
    2024-10-15: 6.1M2024-10-31: 8.6M2024-11-15: 8.8M2024-11-29: 9.0M2024-12-13: 7.5M2024-12-31: 8.0M2025-01-15: 9.0M2025-01-31: 9.8M2025-02-14: 8.7M2025-02-28: 7.8M2025-03-14: 7.8M2025-03-31: 8.2M2025-04-15: 7.8M2025-04-30: 7.7M2025-05-15: 8.8M2025-05-30: 12.2M2025-06-13: 18.9M2025-06-30: 24.4M2025-07-15: 27.7M2025-07-31: 26.4M2025-08-15: 29.2M2025-08-29: 29.3M2025-09-15: 20.9M2025-09-30: 23.1M2025-10-15: 25.1M
    the 15 Oct 2025 report24 earlier reportsnormal: 8.9M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Short interest and volume: Short interest spike became public on 13 Nov 2025

    SELLAS Life Sciences had 29.0M shares sold short in the 31 Oct 2025 report, 3.4× the same report last year.

    This period
    29.0M (the 31 Oct 2025 report)
    Normal report (median of 24 earlier)
    9.0M
    Typical spread (median absolute deviation)
    1.3M
    How far from its usual level
    +10.5
    Same report last year
    8.6M
    History used
    2,849 days
    2024-10-31: 8.6M2024-11-15: 8.8M2024-11-29: 9.0M2024-12-13: 7.5M2024-12-31: 8.0M2025-01-15: 9.0M2025-01-31: 9.8M2025-02-14: 8.7M2025-02-28: 7.8M2025-03-14: 7.8M2025-03-31: 8.2M2025-04-15: 7.8M2025-04-30: 7.7M2025-05-15: 8.8M2025-05-30: 12.2M2025-06-13: 18.9M2025-06-30: 24.4M2025-07-15: 27.7M2025-07-31: 26.4M2025-08-15: 29.2M2025-08-29: 29.3M2025-09-15: 20.9M2025-09-30: 23.1M2025-10-15: 25.1M2025-10-31: 29.0M
    the 31 Oct 2025 report24 earlier reportsnormal: 9.0M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Short interest and volume: Short interest spike became public on 26 Nov 2025

    SELLAS Life Sciences had 31.8M shares sold short in the 14 Nov 2025 report, 3.6× the same report last year.

    This period
    31.8M (the 14 Nov 2025 report)
    Normal report (median of 24 earlier)
    9.4M
    Typical spread (median absolute deviation)
    1.8M
    How far from its usual level
    +8.2
    Same report last year
    8.8M
    History used
    2,863 days
    2024-11-15: 8.8M2024-11-29: 9.0M2024-12-13: 7.5M2024-12-31: 8.0M2025-01-15: 9.0M2025-01-31: 9.8M2025-02-14: 8.7M2025-02-28: 7.8M2025-03-14: 7.8M2025-03-31: 8.2M2025-04-15: 7.8M2025-04-30: 7.7M2025-05-15: 8.8M2025-05-30: 12.2M2025-06-13: 18.9M2025-06-30: 24.4M2025-07-15: 27.7M2025-07-31: 26.4M2025-08-15: 29.2M2025-08-29: 29.3M2025-09-15: 20.9M2025-09-30: 23.1M2025-10-15: 25.1M2025-10-31: 29.0M2025-11-14: 31.8M
    the 14 Nov 2025 report24 earlier reportsnormal: 9.4M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Short interest and volume: Short interest spike became public on 10 Dec 2025

    SELLAS Life Sciences had 33.3M shares sold short in the 28 Nov 2025 report, 3.7× the same report last year.

    This period
    33.3M (the 28 Nov 2025 report)
    Normal report (median of 24 earlier)
    11.0M
    Typical spread (median absolute deviation)
    3.4M
    How far from its usual level
    +4.4
    Same report last year
    9.0M
    History used
    2,877 days
    2024-11-29: 9.0M2024-12-13: 7.5M2024-12-31: 8.0M2025-01-15: 9.0M2025-01-31: 9.8M2025-02-14: 8.7M2025-02-28: 7.8M2025-03-14: 7.8M2025-03-31: 8.2M2025-04-15: 7.8M2025-04-30: 7.7M2025-05-15: 8.8M2025-05-30: 12.2M2025-06-13: 18.9M2025-06-30: 24.4M2025-07-15: 27.7M2025-07-31: 26.4M2025-08-15: 29.2M2025-08-29: 29.3M2025-09-15: 20.9M2025-09-30: 23.1M2025-10-15: 25.1M2025-10-31: 29.0M2025-11-14: 31.8M2025-11-28: 33.3M
    the 28 Nov 2025 report24 earlier reportsnormal: 11.0M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

  15. 14 Aug 2025Institutional holdings change

    saw 38 13F filers open a new position in the quarter ended 30 Jun 2025, 4.8× the same quarter last year.

    Same quarter last year: 8; its normal quarter is 7.5.

    See the evidence
    This period
    38 (the quarter ended 30 Jun 2025)
    Normal quarter (median of 8 earlier)
    7.5
    Typical spread (median absolute deviation)
    2
    How far from its usual level
    +10.2
    Same quarter last year
    8
    History used
    2,648 days
    2023-06-30: 32023-09-30: 32023-12-31: 82024-03-31: 72024-06-30: 82024-09-30: 82024-12-31: 42025-03-31: 172025-06-30: 38
    the quarter ended 30 Jun 20258 earlier quartersnormal: 7.5

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

    Check it at the source: SEC Form 13F data sets.

  16. 12 Aug 2025Short interest and volume change

    had 26.4M shares sold short in the 31 Jul 2025 report, 2.5× the same report last year.

    Same report last year: 10.7M; its normal report is 8.4M.

    See the evidence
    This period
    26.4M (the 31 Jul 2025 report)
    Normal report (median of 24 earlier)
    8.4M
    Typical spread (median absolute deviation)
    621K
    How far from its usual level
    +19.6
    Same report last year
    10.7M
    History used
    2,757 days
    2024-07-31: 10.7M2024-08-15: 7.7M2024-08-30: 8.2M2024-09-13: 8.2M2024-09-30: 8.2M2024-10-15: 6.1M2024-10-31: 8.6M2024-11-15: 8.8M2024-11-29: 9.0M2024-12-13: 7.5M2024-12-31: 8.0M2025-01-15: 9.0M2025-01-31: 9.8M2025-02-14: 8.7M2025-02-28: 7.8M2025-03-14: 7.8M2025-03-31: 8.2M2025-04-15: 7.8M2025-04-30: 7.7M2025-05-15: 8.8M2025-05-30: 12.2M2025-06-13: 18.9M2025-06-30: 24.4M2025-07-15: 27.7M2025-07-31: 26.4M
    the 31 Jul 2025 report24 earlier reportsnormal: 8.4M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  17. 25 Jul 2025Short interest and volume change

    had 27.7M shares sold short in the 15 Jul 2025 report, 2.9× the same report last year.

    Same report last year: 9.7M; its normal report is 8.4M.

    See the evidence
    This period
    27.7M (the 15 Jul 2025 report)
    Normal report (median of 24 earlier)
    8.4M
    Typical spread (median absolute deviation)
    621K
    How far from its usual level
    +21.0
    Same report last year
    9.7M
    History used
    2,741 days
    2024-07-15: 9.7M2024-07-31: 10.7M2024-08-15: 7.7M2024-08-30: 8.2M2024-09-13: 8.2M2024-09-30: 8.2M2024-10-15: 6.1M2024-10-31: 8.6M2024-11-15: 8.8M2024-11-29: 9.0M2024-12-13: 7.5M2024-12-31: 8.0M2025-01-15: 9.0M2025-01-31: 9.8M2025-02-14: 8.7M2025-02-28: 7.8M2025-03-14: 7.8M2025-03-31: 8.2M2025-04-15: 7.8M2025-04-30: 7.7M2025-05-15: 8.8M2025-05-30: 12.2M2025-06-13: 18.9M2025-06-30: 24.4M2025-07-15: 27.7M
    the 15 Jul 2025 report24 earlier reportsnormal: 8.4M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  18. 26 Jun 2025Short interest and volume change

    had 18.9M shares sold short in the 13 Jun 2025 report, 2.5× the same report last year.

    Same report last year: 7.6M; its normal report is 8.2M.

    See the evidence
    This period
    18.9M (the 13 Jun 2025 report)
    Normal report (median of 24 earlier)
    8.2M
    Typical spread (median absolute deviation)
    524K
    How far from its usual level
    +13.1
    Same report last year
    7.6M
    History used
    2,709 days
    2024-06-14: 7.6M2024-06-28: 8.9M2024-07-15: 9.7M2024-07-31: 10.7M2024-08-15: 7.7M2024-08-30: 8.2M2024-09-13: 8.2M2024-09-30: 8.2M2024-10-15: 6.1M2024-10-31: 8.6M2024-11-15: 8.8M2024-11-29: 9.0M2024-12-13: 7.5M2024-12-31: 8.0M2025-01-15: 9.0M2025-01-31: 9.8M2025-02-14: 8.7M2025-02-28: 7.8M2025-03-14: 7.8M2025-03-31: 8.2M2025-04-15: 7.8M2025-04-30: 7.7M2025-05-15: 8.8M2025-05-30: 12.2M2025-06-13: 18.9M
    the 13 Jun 2025 report24 earlier reportsnormal: 8.2M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  19. 14 Jun 2025Insiders record

    VAN NOSTRAND ROBERT L (director) bought 10,000 shares of SLS ($14,800) (dated 13 Jun 2025)

  20. 11 Jun 2025Short interest and volume change

    had 12.2M shares sold short in the 30 May 2025 report, 1.6× the same report last year.

    Same report last year: 7.6M; its normal report is 8.2M.

    See the evidence
    This period
    12.2M (the 30 May 2025 report)
    Normal report (median of 24 earlier)
    8.2M
    Typical spread (median absolute deviation)
    504K
    How far from its usual level
    +4.9
    Same report last year
    7.6M
    History used
    2,695 days
    2024-05-31: 7.6M2024-06-14: 7.6M2024-06-28: 8.9M2024-07-15: 9.7M2024-07-31: 10.7M2024-08-15: 7.7M2024-08-30: 8.2M2024-09-13: 8.2M2024-09-30: 8.2M2024-10-15: 6.1M2024-10-31: 8.6M2024-11-15: 8.8M2024-11-29: 9.0M2024-12-13: 7.5M2024-12-31: 8.0M2025-01-15: 9.0M2025-01-31: 9.8M2025-02-14: 8.7M2025-02-28: 7.8M2025-03-14: 7.8M2025-03-31: 8.2M2025-04-15: 7.8M2025-04-30: 7.7M2025-05-15: 8.8M2025-05-30: 12.2M
    the 30 May 2025 report24 earlier reportsnormal: 8.2M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  21. 6 Jun 2025Filings record

    Changed its auditor

  22. 3 Jun 2025Insiders record

    Wasman Jane (director) bought 20,000 shares of SLS ($33,800) (dated 2 Jun 2025)

  23. 23 May 2025Insiders record

    Kalin Katherine Bach (director) bought 20,000 shares of SLS ($36,000) (dated 22 May 2025)

  24. 16 Jan 2025Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  25. 16 Jan 2025Filings record

    Director or officer change

  26. 25 Apr 2024Short interest and volume change

    had 5.7M shares sold short in the 15 Apr 2024 report, 4.8× the same report last year.

    Same report last year: 1.2M; its normal report is 1.6M.

    See the evidence
    This period
    5.7M (the 15 Apr 2024 report)
    Normal report (median of 24 earlier)
    1.6M
    Typical spread (median absolute deviation)
    592K
    How far from its usual level
    +4.6
    Same report last year
    1.2M
    History used
    2,285 days
    2023-04-14: 1.2M2023-04-28: 1.2M2023-05-15: 1.3M2023-05-31: 1.2M2023-06-15: 1.1M2023-06-30: 1.2M2023-07-14: 1.2M2023-07-31: 1.2M2023-08-15: 1.1M2023-08-31: 1.1M2023-09-15: 1.0M2023-09-29: 1.1M2023-10-13: 2.0M2023-10-31: 3.0M2023-11-15: 4.6M2023-11-30: 4.6M2023-12-15: 4.7M2023-12-29: 4.7M2024-01-12: 3.9M2024-01-31: 3.1M2024-02-15: 3.9M2024-02-29: 4.5M2024-03-15: 5.2M2024-03-28: 5.3M2024-04-15: 5.7M
    the 15 Apr 2024 report24 earlier reportsnormal: 1.6M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  27. 10 Apr 2024Short interest and volume change

    had 5.3M shares sold short in the 28 Mar 2024 report, 4.8× the same report last year.

    Same report last year: 1.1M; its normal report is 1.2M.

    See the evidence
    This period
    5.3M (the 28 Mar 2024 report)
    Normal report (median of 24 earlier)
    1.2M
    Typical spread (median absolute deviation)
    175K
    How far from its usual level
    +15.6
    Same report last year
    1.1M
    History used
    2,267 days
    2023-03-31: 1.1M2023-04-14: 1.2M2023-04-28: 1.2M2023-05-15: 1.3M2023-05-31: 1.2M2023-06-15: 1.1M2023-06-30: 1.2M2023-07-14: 1.2M2023-07-31: 1.2M2023-08-15: 1.1M2023-08-31: 1.1M2023-09-15: 1.0M2023-09-29: 1.1M2023-10-13: 2.0M2023-10-31: 3.0M2023-11-15: 4.6M2023-11-30: 4.6M2023-12-15: 4.7M2023-12-29: 4.7M2024-01-12: 3.9M2024-01-31: 3.1M2024-02-15: 3.9M2024-02-29: 4.5M2024-03-15: 5.2M2024-03-28: 5.3M
    the 28 Mar 2024 report24 earlier reportsnormal: 1.2M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  28. 29 Mar 2024Filings record

    Private placement of securities (Form D)

  29. 27 Mar 2024Short interest and volume change

    had 5.2M shares sold short in the 15 Mar 2024 report, 4.3× the same report last year.

    Same report last year: 1.2M; its normal report is 1.2M.

    See the evidence
    This period
    5.2M (the 15 Mar 2024 report)
    Normal report (median of 24 earlier)
    1.2M
    Typical spread (median absolute deviation)
    116K
    How far from its usual level
    +23.0
    Same report last year
    1.2M
    History used
    2,254 days
    2023-03-15: 1.2M2023-03-31: 1.1M2023-04-14: 1.2M2023-04-28: 1.2M2023-05-15: 1.3M2023-05-31: 1.2M2023-06-15: 1.1M2023-06-30: 1.2M2023-07-14: 1.2M2023-07-31: 1.2M2023-08-15: 1.1M2023-08-31: 1.1M2023-09-15: 1.0M2023-09-29: 1.1M2023-10-13: 2.0M2023-10-31: 3.0M2023-11-15: 4.6M2023-11-30: 4.6M2023-12-15: 4.7M2023-12-29: 4.7M2024-01-12: 3.9M2024-01-31: 3.1M2024-02-15: 3.9M2024-02-29: 4.5M2024-03-15: 5.2M
    the 15 Mar 2024 report24 earlier reportsnormal: 1.2M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  30. 12 Mar 2024Short interest and volume change

    had 4.5M shares sold short in the 29 Feb 2024 report, 3.5× the same report last year.

    Same report last year: 1.3M; its normal report is 1.2M.

    See the evidence
    This period
    4.5M (the 29 Feb 2024 report)
    Normal report (median of 24 earlier)
    1.2M
    Typical spread (median absolute deviation)
    100K
    How far from its usual level
    +22.3
    Same report last year
    1.3M
    History used
    2,239 days
    2023-02-28: 1.3M2023-03-15: 1.2M2023-03-31: 1.1M2023-04-14: 1.2M2023-04-28: 1.2M2023-05-15: 1.3M2023-05-31: 1.2M2023-06-15: 1.1M2023-06-30: 1.2M2023-07-14: 1.2M2023-07-31: 1.2M2023-08-15: 1.1M2023-08-31: 1.1M2023-09-15: 1.0M2023-09-29: 1.1M2023-10-13: 2.0M2023-10-31: 3.0M2023-11-15: 4.6M2023-11-30: 4.6M2023-12-15: 4.7M2023-12-29: 4.7M2024-01-12: 3.9M2024-01-31: 3.1M2024-02-15: 3.9M2024-02-29: 4.5M
    the 29 Feb 2024 report24 earlier reportsnormal: 1.2M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  31. 8 Mar 2024Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  32. 8 Mar 2024Filings record

    Director or officer change

  33. 28 Feb 2024Short interest and volume change

    had 3.9M shares sold short in the 15 Feb 2024 report, 3.2× the same report last year.

    Same report last year: 1.2M; its normal report is 1.2M.

    See the evidence
    This period
    3.9M (the 15 Feb 2024 report)
    Normal report (median of 24 earlier)
    1.2M
    Typical spread (median absolute deviation)
    84K
    How far from its usual level
    +21.6
    Same report last year
    1.2M
    History used
    2,225 days
    2023-02-15: 1.2M2023-02-28: 1.3M2023-03-15: 1.2M2023-03-31: 1.1M2023-04-14: 1.2M2023-04-28: 1.2M2023-05-15: 1.3M2023-05-31: 1.2M2023-06-15: 1.1M2023-06-30: 1.2M2023-07-14: 1.2M2023-07-31: 1.2M2023-08-15: 1.1M2023-08-31: 1.1M2023-09-15: 1.0M2023-09-29: 1.1M2023-10-13: 2.0M2023-10-31: 3.0M2023-11-15: 4.6M2023-11-30: 4.6M2023-12-15: 4.7M2023-12-29: 4.7M2024-01-12: 3.9M2024-01-31: 3.1M2024-02-15: 3.9M
    the 15 Feb 2024 report24 earlier reportsnormal: 1.2M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  34. 16 Feb 2024Filings record

    Delisting notice or listing transfer

  35. 10 Feb 2024Short interest and volume change

    had 3.1M shares sold short in the 31 Jan 2024 report, 2.7× the same report last year.

    Same report last year: 1.2M; its normal report is 1.2M.

    See the evidence
    This period
    3.1M (the 31 Jan 2024 report)
    Normal report (median of 24 earlier)
    1.2M
    Typical spread (median absolute deviation)
    70K
    How far from its usual level
    +16.1
    Same report last year
    1.2M
    History used
    2,210 days
    2023-01-31: 1.2M2023-02-15: 1.2M2023-02-28: 1.3M2023-03-15: 1.2M2023-03-31: 1.1M2023-04-14: 1.2M2023-04-28: 1.2M2023-05-15: 1.3M2023-05-31: 1.2M2023-06-15: 1.1M2023-06-30: 1.2M2023-07-14: 1.2M2023-07-31: 1.2M2023-08-15: 1.1M2023-08-31: 1.1M2023-09-15: 1.0M2023-09-29: 1.1M2023-10-13: 2.0M2023-10-31: 3.0M2023-11-15: 4.6M2023-11-30: 4.6M2023-12-15: 4.7M2023-12-29: 4.7M2024-01-12: 3.9M2024-01-31: 3.1M
    the 31 Jan 2024 report24 earlier reportsnormal: 1.2M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  36. 25 Jan 2024Short interest and volume change

    had 3.9M shares sold short in the 12 Jan 2024 report, 3.2× the same report last year.

    Same report last year: 1.2M; its normal report is 1.2M.

    See the evidence
    This period
    3.9M (the 12 Jan 2024 report)
    Normal report (median of 24 earlier)
    1.2M
    Typical spread (median absolute deviation)
    62K
    How far from its usual level
    +22.5
    Same report last year
    1.2M
    History used
    2,191 days
    2023-01-13: 1.2M2023-01-31: 1.2M2023-02-15: 1.2M2023-02-28: 1.3M2023-03-15: 1.2M2023-03-31: 1.1M2023-04-14: 1.2M2023-04-28: 1.2M2023-05-15: 1.3M2023-05-31: 1.2M2023-06-15: 1.1M2023-06-30: 1.2M2023-07-14: 1.2M2023-07-31: 1.2M2023-08-15: 1.1M2023-08-31: 1.1M2023-09-15: 1.0M2023-09-29: 1.1M2023-10-13: 2.0M2023-10-31: 3.0M2023-11-15: 4.6M2023-11-30: 4.6M2023-12-15: 4.7M2023-12-29: 4.7M2024-01-12: 3.9M
    the 12 Jan 2024 report24 earlier reportsnormal: 1.2M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  37. 11 Jan 2024Short interest and volume change

    had 4.7M shares sold short in the 29 Dec 2023 report, 3.8× the same report last year.

    Same report last year: 1.2M; its normal report is 1.2M.

    See the evidence
    This period
    4.7M (the 29 Dec 2023 report)
    Normal report (median of 24 earlier)
    1.2M
    Typical spread (median absolute deviation)
    59K
    How far from its usual level
    +29.6
    Same report last year
    1.2M
    History used
    2,177 days
    2022-12-30: 1.2M2023-01-13: 1.2M2023-01-31: 1.2M2023-02-15: 1.2M2023-02-28: 1.3M2023-03-15: 1.2M2023-03-31: 1.1M2023-04-14: 1.2M2023-04-28: 1.2M2023-05-15: 1.3M2023-05-31: 1.2M2023-06-15: 1.1M2023-06-30: 1.2M2023-07-14: 1.2M2023-07-31: 1.2M2023-08-15: 1.1M2023-08-31: 1.1M2023-09-15: 1.0M2023-09-29: 1.1M2023-10-13: 2.0M2023-10-31: 3.0M2023-11-15: 4.6M2023-11-30: 4.6M2023-12-15: 4.7M2023-12-29: 4.7M
    the 29 Dec 2023 report24 earlier reportsnormal: 1.2M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  38. 3 Jan 2024Filings record

    A major agreement ended

  39. 28 Dec 2023Short interest and volume change

    had 4.7M shares sold short in the 15 Dec 2023 report, 3.8× the same report last year.

    Same report last year: 1.2M; its normal report is 1.2M.

    See the evidence
    This period
    4.7M (the 15 Dec 2023 report)
    Normal report (median of 24 earlier)
    1.2M
    Typical spread (median absolute deviation)
    51K
    How far from its usual level
    +29.0
    Same report last year
    1.2M
    History used
    2,163 days
    2022-12-15: 1.2M2022-12-30: 1.2M2023-01-13: 1.2M2023-01-31: 1.2M2023-02-15: 1.2M2023-02-28: 1.3M2023-03-15: 1.2M2023-03-31: 1.1M2023-04-14: 1.2M2023-04-28: 1.2M2023-05-15: 1.3M2023-05-31: 1.2M2023-06-15: 1.1M2023-06-30: 1.2M2023-07-14: 1.2M2023-07-31: 1.2M2023-08-15: 1.1M2023-08-31: 1.1M2023-09-15: 1.0M2023-09-29: 1.1M2023-10-13: 2.0M2023-10-31: 3.0M2023-11-15: 4.6M2023-11-30: 4.6M2023-12-15: 4.7M
    the 15 Dec 2023 report24 earlier reportsnormal: 1.2M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  40. 12 Dec 2023Short interest and volume change

    had 4.6M shares sold short in the 30 Nov 2023 report, 3.8× the same report last year.

    Same report last year: 1.2M; its normal report is 1.2M.

    See the evidence
    This period
    4.6M (the 30 Nov 2023 report)
    Normal report (median of 24 earlier)
    1.2M
    Typical spread (median absolute deviation)
    43K
    How far from its usual level
    +28.6
    Same report last year
    1.2M
    History used
    2,148 days
    2022-11-30: 1.2M2022-12-15: 1.2M2022-12-30: 1.2M2023-01-13: 1.2M2023-01-31: 1.2M2023-02-15: 1.2M2023-02-28: 1.3M2023-03-15: 1.2M2023-03-31: 1.1M2023-04-14: 1.2M2023-04-28: 1.2M2023-05-15: 1.3M2023-05-31: 1.2M2023-06-15: 1.1M2023-06-30: 1.2M2023-07-14: 1.2M2023-07-31: 1.2M2023-08-15: 1.1M2023-08-31: 1.1M2023-09-15: 1.0M2023-09-29: 1.1M2023-10-13: 2.0M2023-10-31: 3.0M2023-11-15: 4.6M2023-11-30: 4.6M
    the 30 Nov 2023 report24 earlier reportsnormal: 1.2M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

Showing the newest 40 of 105 entries; narrow the window or the kind of data to see older ones.

Not listed: 216 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.

Identifiers and sources

How records are matched to this company, and what each source holds for it

Cik
0001390478
Ticker
SLS
Domain
sellaslifesciences.com
Employer name
SELLAS LIFE SCIENCES GROUP INC. (1 unverified)
Fein
20-8099512 (1 unverified)
Hq location
NY|NEW YORK|10036 (1 unverified)
Name
GALENA BIOPHARMA, INC., (Name under which subsidiary does business), RXI PHARMACEUTICALS CORP, SELLAS Life Sciences Group, Inc. and 2 more
  • DOL H-1B labor condition applications and PERM certifications5 data points20 Apr 2026 to 20 Apr 2026
  • SEC Form 13F institutional holdings315 data points31 Mar 2018 to 30 Sep 2026
  • SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)262 records7 Jan 2016 to 20 Nov 2026
  • SEC XBRL company facts (revenue, capex, R&D, backlog...)878 data points31 Dec 2009 to 11 Nov 2026
  • SEC Form 4 insider transactions17 records, 44 data points7 Jun 2016 to 20 Nov 2026
  • FINRA short interest (twice monthly)621 data points12 Jan 2018 to 30 Oct 2026
  • FINRA daily short sale volume (off-exchange)4178 data points1 Aug 2018 to 20 Nov 2026